Immuron Limited (IMRN)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Revenue
- 7,287,002 48.6%
- Net income
- -5,215,987
- Gross profit
- 4,765,099
- Operating income
- -5,344,548
- Earnings per share
- -2.26
- R&D expense
- 3,597,296
Growth and profitability
- Gross margin
- 65.39
- Operating margin
- -73.34
- Net margin
- -71.58
- Return on equity
- -64.64
- Return on assets
- -51.49
Balance sheet
- Total assets
- 10,129,842
- Total liabilities
- 2,060,787
- Shareholders' equity
- 8,069,055
- Cash and equivalents
- 2,830,526
- Current ratio
- 5.09
Cash flow and ratios
- Operating cash flow
- -6,136,949
Shareholder returns
- Shares outstanding
- 322,848,081
- Book value per share
- 0.02
Company information
- Headquarters
- Carlton, Victoria, C3
- Exchange
- NASDAQ
- Fiscal year end
- 06-30
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
Immuron Limited trades on NASDAQ under the ticker symbol IMRN. This page brings together its price chart, company profile, key financial figures and technical indicators.